Clinical Research Directory

Inclusion Criteria: 1. WHO scores 0-2; 2. The primary lesion was confirmed by pathology or cytology; 3. The metastatic lesions were diagnosed by imaging(CT,MRI,PET-CT,ECT),or the lesions were confirmed by biopsy; 4. The metastatic lesion was limited in 3 consecutive vertebral bodies; 5. The baseline pain score was ≥5(NRPS) and the use of analgesic drugs was recorded; 6. The enhanced MRI scan of involved vertebral bodies was required in the 2 weeks before radiotherapy; Adequate bone marrow, hepatic and renal function as assessed by the following laboratory requirements conducted within 7 days of starting study treatment: 1. Leukocytes ≥ 3.0 x109/ L; 2. Absolute neutrophil count (ANC) ≥ 1.5 x109/ L; 3. Platelet count ≥ 100 x109/ L; 4. Hemoglobin (Hb) ≥ 9g/ dL; 5. Total bilirubin ≤1.5 x the upper limit of normal (ULN); 6. Alanine aminotransferase (ALT) ≤ 3 x ULN; 7. Aspartate aminotransferase (AST) ≤ 3 x ULN; 8. Serum creatinine ≤ 1.5 x the ULN; 9. Signed informed consent; Exclusion Criteria: 1. There were significant changes in the shape of the vertebral body (the height of the vertebral body was compressed≥ 50%) or the vertebral body was unchanged but the volume of the dissolving bone was≥ 50% and could lead to serious bone adverse events; 2. There were \>3 consecutive vertebral bodies involved; 3. Spinal cord compression has occurred; 4. The gap between tumor and spinal cord was less than 3mm; 5. The metastatic area previously received radiation; 6. Pregnant and Nursing women; 7. Uncontrolled co-morbid illnesses; 9.refused to signed informed consent;